The changes in MGMT promoter methylation status in initial and recurrent glioblastomas

Translational Oncology

Volumn 5, Issue 5, 2012, Pages 393-397

  Park, Chul Kee ^a   Kim, Ja Eun ^a   Kim, Ji Young ^a   Song, Sang Woo ^a   Kim, Jin Wook ^a   Choi, Seung Hong ^a   Kim, Tae Min ^a   Lee, Se Hoon ^a   Kim, Il Han ^a   Park, Sung Hye ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MISMATCH REPAIR PROTEIN; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENETIC VARIABILITY; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; TISSUE SECTION;

EID: 84867518753     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12253     Document Type: Article

References (23)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
2. Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M, Steiger HJ, Friedensdorf B, Reifenberger G, and Sabel MC (2009). Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 15, 6683-6693.
3. 6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26, 4189-4199.
4. Kaina B, Christmann M, Naumann S, and RoosWP(2007). MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 6, 1079-1099.
5. Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, et al. (2010). Phase II trial of continuous doseintense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28, 2051-2057.
6. Kaina B and Christmann M (2002). DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther 40, 354-367.
7. Martinez R, Schackert HK, Plaschke J, Baretton G, Appelt H, and Schackert G (2004). Molecular mechanisms associated with chromosomal and microsatellite instability in sporadic glioblastoma multiforme. Oncology 66, 395-403.
8. Martinez R, Schackert HK, Appelt H, Plaschke J, Baretton G, and Schackert G (2005). Low-level microsatellite instability phenotype in sporadic glioblastoma multiforme. J Cancer Res Clin Oncol 131, 87-93.
9. Alonso M, Hamelin R, Kim M, Porwancher K, Sung T, Parhar P, Miller DC, and Newcomb EW (2001). Microsatellite instability occurs in distinct subtypes of pediatric but not adult central nervous system tumors. Cancer Res 61, 2124-2128.
10. Eckert A, Kloor M, Giersch A, Ahmadi R, Herold-Mende C, Hampl JA, Heppner FL, Zoubaa S, Holinski-Feder E, Pietsch T, et al. (2007). Microsatellite instability in pediatric and adult high-grade gliomas. Brain Pathol 17, 146-150.
11. Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS, Rasheed A, Quinn JA, Ali-Osman F, Friedman AH, Modrich PL, et al. (2008). Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 14, 4859-4868.
12. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Loffler M, et al. (2011). Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 129, 659-670.
13. Park CK, Kim J, Yim SY, Lee AR, Han JH, Kim CY, Park SH, Kim TM, Lee SH, Choi SH, et al. (2011). Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. Neuro Oncol 13, 195-202.
14. Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, Sijben A, Boots-Sprenger SH, and Wesseling P (2007). MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87, 1055-1065.
15. 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol 87, 71-78.
16. Jung TY, Jung S, Moon KS, Kim IY, Kang SS, Kim YH, Park CS, and Lee KH (2010). Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. Oncol Rep 23, 1269-1276.
17. 6-methylguanine DNAmethyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol 12, 283-288.
18. Christmann M, Nagel G, Horn S, Krahn U, Wiewrodt D, Sommer C, and Kaina B (2010). MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer 127, 2106-2118.
19. Shah N, Lin B, Sibenaller Z, Ryken T, Lee H, Yoon JG, Rostad S, and Foltz G (2011). Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. PLoS One 6, e16146.
20. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, et al. (2007). Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13, 2038-2045.
21. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S, Bignell G, Davies H, et al. (2006). A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66, 3987-3991.
22. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, and Louis DN (2009). MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 15, 4622-4629.
23. Umar A, Risinger JI, Glaab WE, Tindall KR, Barrett JC, and Kunkel TA (1998). Functional overlap in mismatch repair by human MSH3 and MSH6. Genetics 148, 1637-1646.